TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12939546
Drug: Rate control
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rate control combined with antithrombotic therapy
Study: 12939546
Drug: Rhythm control
Normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm control combined with antithrombotic therapy
Study: 12939546
Drug: Efficacy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efficacy and safety of drugs used in treating AF
Study: 10730228
Drug: 36 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 Gy radiation treatment
Study: 10730228
Drug: 10 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 Gy radiation treatment
Study: 10730228
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no radiation treatment)
Study: 8931411
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa therapy (10 million U three times a week for 16 weeks)
Study: 2071783
Drug: 10 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 months of immunotherapy (IT) at 2 micrograms of Amb a I
Study: 2071783
Drug: 22 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 months of immunotherapy (IT) at 24 micrograms of Amb a I
Study: 2071783
Drug: 1 year
Normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year of immunotherapy (IT) at 2 micrograms of Amb a I
Study: 2071783
Drug: 2 years
Normalized name: Childrens Panadol 5 - 12 Years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 years of immunotherapy (IT) at 2 micrograms of Amb a I
Study: 2071783
Drug: 3 years
Normalized name: NanoVM 1-3 years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 years of immunotherapy (IT) at 24 micrograms of Amb a I
Study: 6129719
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 to 320 mg per day for 6 to 31 months)
Study: 26363342
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of autologous, unfractionated bone marrow
Study: 26467901
Drug: Placebo intervention:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intervention: infusion of autologous blood
Study: 20041782
Drug: Yeast hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast hydrolysate (YH) administered for 2 weeks
Study: 18605225
Drug: COLD-fX (immune-modulator)
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COLD-fX (immune-modulator)
Study: 18605225
Drug: REMEMBER-fX (neuro-modulator)
Normalized name: Prevail-FX
Approvals — FDA: no, EMA: no, PMDA: no
Description: REMEMBER-fX (neuro-modulator)
Study: 15234398
Drug: HDB tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDB tirofiban (25 microg/kg/3 min, and infusion of 0.15 microg/kg/min for 24 to 48 h)
Study: 8378292
Drug: DA Salbutamol/DNCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA Salbutamol/DNCG (0.1 mg Salbutamol and 1.0 mg DNCG/puff)
Study: 8378292
Drug: DA Salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DA Salbutamol alone (0.1 mg Salbutamol puff)
Study: 3527070
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide and droperidol (regimen I)
Study: 3527070
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high-dose metoclopramide, droperidol and methylprednisolone (regimen II)
Study: 31470006
Drug: Small-intestinal-release peppermint
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-intestinal-release peppermint oil (182 mg)
Study: 31470006
Drug: Ileocolonic-release peppermint
Normalized name: Peppermint
DrugBank: Peppermint (DB10984)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ileocolonic-release peppermint oil (182 mg)
Study: 20516031
Drug: DMARD monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMARD monotherapy
Study: 18982929
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg simvastatin per day
Study: 16092581
Drug: Sustained-release bupropion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release bupropion, 300 mg/d
Study: 12585148
Drug: Danxiaoling Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danxiaoling Pill (DXLP)
Study: 11869855
Drug: Intracoronary estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary estrogen administration
Study: 7924241
Drug: Individual Treatment
Normalized name: Alex Rubber Tip Individual Pack 3/4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Treatment (IT)
Study: 7924241
Drug: Individual Treatment
Normalized name: Alex Rubber Tip Individual Pack 3/4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Treatment (Rehearsal IT)
Study: 2573963
Drug: Antacids and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids and cholinolytics
Study: 4840431
Drug: Buffered cephalothin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered cephalothin solution
Study: 4840431
Drug: Unbuffered cephalothin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unbuffered cephalothin solution
Study: 31167050
Drug: Azithromycin (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (twice yearly for 2 years, followed by additional distributions in MORDOR II)
Study: 22068177
Drug: P6: home
Approvals — FDA: no, EMA: no, PMDA: no
Description: P6: home use chlorine solution (Q'boa® at 0.45% for 10 min)
Study: 17013635
Drug: Acute tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute tryptophan depletion (capsules containing an amino acid mixture specifically lacking tryptophan)
Study: 11045790
Drug: fenretinide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenretinide (200 mg day p.o. for 24 months)
Study: 25869467
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic and steroid combination (ofloxacin 0.26% and dexamethasone 0.053% nasal drops) for 10 days, administered intranasally (5 drops in each nostril/8 hours)
Study: 25869467
Drug: Oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotic alone (amoxicillin 90 mg/kg)
Study: 21612429
Drug: Guarana 50
Normalized name: GUARANA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guarana 50 mg by mouth twice daily
Study: 19824119
Drug: Intramuscular meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meperidine (n = 30)
Study: 16805714
Drug: Combination regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimens with chemotherapy and/or biological therapy
Study: 8167785
Drug: Placebo/control treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/control treatment
Study: 2964981
Drug: Intensified conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified conventional treatment (ICT) using the NovoPen
Study: 30301187
Drug: SOC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC plus vaccination with Audencel (weekly intranodal application in weeks 7 to 10, followed by monthly intervals)
Study: 18637156
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg of imidafenacin/day
Study: 18637156
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg of imidafenacin/day
Study: 18637156
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of imidafenacin/day
Study: 17436825
Drug: ER-minocycline 1
Normalized name: meclocycline
DrugBank: Meclocycline (DB13092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ER-minocycline 1 mg/kg
Study: 17436825
Drug: ER-minocycline 2
Normalized name: meclocycline
DrugBank: Meclocycline (DB13092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ER-minocycline 2 mg/kg
Study: 17436825
Drug: ER-minocycline 3
Normalized name: meclocycline
DrugBank: Meclocycline (DB13092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ER-minocycline 3 mg/kg
Study: 8798927
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of tramadol (Protradon and Tramal)
Study: 1335441
Drug: GU‐052 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GU‐052 (3 x 4 g daily)
Study: 1335441
Drug: Glucotard (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucotard (3 x 5 g daily)
Study: 6693703
Drug: Clinical pharmacists
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacists prescribing drug therapy
Study: 24679469
Drug: Guselkumab 10
Normalized name: guselkumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 10 mg
Study: 24679469
Drug: Guselkumab 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 30 mg
Study: 24679469
Drug: Guselkumab 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 300 mg
Study: 24679469
Drug: Guselkumab (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab (combined doses)
Study: 19178747
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise training (walking program to achieve the same weekly physical activity for six months)
Study: 17184435
Drug: Thiopental 5
Normalized name: thiopental 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 5 mg x kg(‐1) i.v. for children up to 3 years; 2.5 mg x kg(‐1) i.v. rescue boluses if needed.
Study: 17184435
Drug: Propofol 1-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1-1.5 mg x kg(‐1) i.v. for children over 3 years; maintained with 0.1-0.15 mg x kg(‐1) x min(‐1) continuous i.v. infusion, increased if needed.
Study: 9394873
Drug: Tricyclic Antidepressant
Normalized name: Tricyclic antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic Antidepressant (TCA)
Study: 24625229
Drug: Bioengineered hyaluronic
Normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioengineered hyaluronic acid (BioHA, 1% sodium hyaluronate) intra-articular injections
Study: 24625229
Drug: Conventional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional care (CC) including NSAIDs and analgesics
Study: 14565628
Drug: Flite Tabs
Normalized name: alkali blite pollen extract
DrugBank: Suaeda moquinii pollen (DB10953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flite Tabs (150 mg pinokinase)
Study: 8828022
Drug: Ebastine 10mg
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 10mg once daily in the morning
Study: 8828022
Drug: Ebastine 20mg
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 20mg once daily in the morning
Study: 8828022
Drug: Ebastine 10mg
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 10mg once daily in the evening
Study: 8828022
Drug: Ebastine 10mg
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 10mg or 20mg once daily (4-month study)
Study: 6360688
Drug: Diltiazem (D)
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem (D) 282 +/- 102 mg/day
Study: 6360688
Drug: Propranolol (P)
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (P) 158 +/- 81 mg/day
Study: 27016862
Drug: Standardized smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized smoking cessation intervention (physician advice, nicotine replacement therapy, referral to counseling)
Study: 19850697
Drug: Randomized treatments
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized treatments (n-3 polyunsaturated fatty acids or rosuvastatin)
Study: 18069598
Drug: Angiotensin AT1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin AT1 receptor antagonists
Study: 12172536
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 6 or more risk characteristics
Study: 10023611
Drug: Therapeutic community
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic community treatment
Study: 7788898
Drug: Praziquantel at
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel at 180 mg/kg bwt for three days
Study: 7788898
Drug: Albendazole at
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole at 90 mg/kg bwt for three days
Study: 7788898
Drug: Praziquantel at
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel at 90 mg/kg bwt plus Albendazole at 45 mg/kg for three days
Study: 7070229
Drug: 0.005 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005 mg/kg of apomorphine
Study: 24875890
Drug: Dexmedetomidine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 2 μg/kg
Study: 19398463
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (1 microg/kg every 4 hours)
Study: 12591004
Drug: Entrox-coated ALA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entrox-coated ALA formulation (6g dose)
Study: 12591004
Drug: Non-coated ALA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-coated ALA formulation (6g dose)
Study: 11194781
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with beta‐agonist and anticholinergic bronchodilators
Study: 8858633
Drug: Intraoperative mitomycin-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative mitomycin-C (0.1 mg/ml applied for 3 minutes)
Study: 8858633
Drug: Topical mitomycin-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mitomycin-C (0.05 mg/ml drops applied for 2 weeks postoperatively)
Study: 1518497
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral antibiotic therapy (non-quinolone)
Study: 6205676
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of 0.1% solution of bleomycin sulphate in normal saline
Study: 24084539
Drug: Mifepristone followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone followed by misoprostol (800 micrograms vaginally followed by 400 micrograms orally every 3 hours, max 4 doses)
Study: 21122577
Drug: 20mg prednisone
Normalized name: prednisone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg prednisone daily for two weeks prior to surveillance colonoscopy
Study: 8877677
Drug: Atorvastatin capsules
Normalized name: atorvastatin Oral Capsule
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin capsules (0.5 to 120 mg)
Study: 8877677
Drug: Atorvastatin solution
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin solution (0.5 to 120 mg)
Study: 24214189
Drug: Topiroxostat 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiroxostat 180 mg
Study: 18003554
Drug: L-dopa administration
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa administration
Study: 18003554
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of STN stimulation and L-dopa
Study: 11022827
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg daily for 3 weeks
Study: 9002496
Drug: Acadesine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acadesine (0.1 mg·kg‐1·min‐1; intravenous infusion for 7 continuous hours and via the cardioplegia solution)
Study: 8455236
Drug: Single intravesical
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravesical instillation of 80 mg epirubicin
Study: 30679293
Drug: internet-delivered cognitive-behavioural
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-delivered cognitive-behavioural therapy (internet-CBT)
Study: 23522518
Drug: Caregiver understanding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver understanding and comfort with administering pain medications.
Study: 15447897
Drug: Iron (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (20 mg)
Study: 15447897
Drug: Zinc (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (20 mg)
Study: 22058086
Drug: Silymarin therapy
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin therapy
Study: 22801961
Drug: Lintuzumab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lintuzumab (600 mg) plus low-dose cytarabine (20 mg subcutaneously twice daily)
Study: 22801961
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus low-dose cytarabine (20 mg subcutaneously twice daily)
Study: 22801961
Drug: Lintuzumab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lintuzumab (600 mg)
Study: 22189801
Drug: Nutritional intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional intervention (dietetic supplement during dialysis containing 355 kcal)
Study: 8850177
Drug: 0.65 g
Normalized name: Tumil-K 2 MEQ/0.65 GM Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.65 g of n‐3 PUFA for 12 weeks
Study: 1378116
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ibopamine
Study: 27358643
Drug: Intrathecal 2
Normalized name: ZICONOTIDE 25MCG/ML INJ INTRATHECAL 20ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 2 mg midazolam
Study: 21073703
Drug: Additional physiotherapy
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional physiotherapy and occupational therapy services on Saturday
Study: 21073703
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care physiotherapy and occupational therapy from Monday to Friday
Study: 19260323
Drug: Puerarin with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerarin with aspirin
Study: 15870588
Drug: Polestriding exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polestriding exercise training (24-week program, 3 times weekly)
Study: 10825304
Drug: Beta-blockers (esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (esmolol infusions on the day of surgery and metoprolol for the next 48 hours)
Study: 6367018
Drug: Allogeneic bone
Normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic bone marrow graft with high dose cyclophosphamide and total body irradiation (8 Gray)
Study: 30335070
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of cortexin
Study: 30335070
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of cortexin
Study: 28091501
Drug: Rac-hopantenic acid
Normalized name: rac-lactic acid
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rac-hopantenic acid (pantogam activ) at a daily dose of 1200 mg for 21 days
Study: 28091501
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with SSRI antidepressants
Study: 25476698
Drug: Acupuncture (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (daily for nine consecutive days on five points, six cycles for a total of 60 days)
Study: 20538079
Drug: Intravenous Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Cefazolin
Study: 8783774
Drug: Remikiren 600
Normalized name: remikiren
DrugBank: Remikiren (DB00212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren 600 mg orally for 8 days
Study: 8783774
Drug: Remikiren 600
Normalized name: remikiren
DrugBank: Remikiren (DB00212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren 600 mg with hydrochlorothiazide 12.5 mg or 25 mg for last 4 days
Study: 8783774
Drug: Remikiren 600
Normalized name: remikiren
DrugBank: Remikiren (DB00212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren 600 mg orally
Study: 30284586
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg hydromorphone (2 mL)
Study: 30284586
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL normal saline intravenously
Study: 26581682
Drug: Cocoa beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa beverage containing 320 mg total cocoa flavanols/day
Study: 25876348
Drug: Moving cupping
Normalized name: chondroitin sulfates
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moving cupping therapy combined with autohemotherapy with acupoint injection (1 mL at each acupoint, once every 3 days)
Study: 25876348
Drug: Cetirizine tablets
Normalized name: cetirizine Oral Tablet
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine tablets (10 mg once daily) and compound dexamethasone acetate cream (once to twice daily)
Study: 25876348
Drug: Moving cupping
Normalized name: chondroitin sulfates
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moving cupping therapy combined with autohemotherapy with acupoint injection
Study: 25876348
Drug: Cetirizine tablets
Normalized name: cetirizine Oral Tablet
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine tablets and compound dexamethasone acetate cream
Study: 20140214
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg FMP2.1 in 0.1 mL AS02(A)
Study: 20140214
Drug: 25 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 microg FMP2.1 in 0.25 mL AS02(A)
Study: 20140214
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg FMP2.1 in 0.5 mL AS02(A)
Study: 20140214
Drug: All malaria
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: All malaria vaccine groups